The average systemic absorption for Cohort C was 743 ng/mL, still way lower than the ABSSSI 0.8 mg/kg arm at 12,000 ng/mL. Since Cohort C showed a dosage/efficacy relationship, a higher dosage (> 200 mg) plus better formulation (foam/gel) should produce even better results in future trials.